Last reviewed · How we verify
Nuedexta
At a glance
| Generic name | Nuedexta |
|---|---|
| Also known as | dextromethorphan hydrobromide and quinidine sulfate, dextromethorphan hydrobromide and quinidine, Dextromethorphan hydrobromide and quinidine sulfate |
| Sponsor | Center for Neurologic Study, La Jolla, California, |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease (PHASE3)
- Impact of Nuedexta on Bulbar Physiology and Function in ALS (PHASE1, PHASE2)
- Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients (PHASE2)
- Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease (PHASE2)
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis (PHASE2)
- Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease (PHASE4)
- Nuedexta in Treatment-Resistant Major Depression (PHASE2)
- Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nuedexta CI brief — competitive landscape report
- Nuedexta updates RSS · CI watch RSS
- Center for Neurologic Study, La Jolla, California, portfolio CI